EVAX实时信号 | 通过Getagraph.com最大化利润

购买 109028 min ago

@ $4.00

发出时间: 14 Feb 2024 @ 04:29

回报率: 7.75%

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:30):

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections...

Stats
今日成交量	4 973.00
平均成交量	94 683.00
市值	22.48M
EPS	$0 ( 2023-12-18 )
下一个收益日期	( $-0.550 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.530
ATR14	$0.0670 (1.67%)

Evaxion Biotech A/S 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Evaxion Biotech A/S 财务报表

Annual	2023
营收:	$73 112.00
毛利润:	$73 112.00 (100.00 %)
EPS:	$-8.11

FY	2023
营收:	$73 112.00
毛利润:	$73 112.00 (100.00 %)
EPS:	$-8.11

FY	2022
营收:	$0
毛利润:	$-571 319 (0.00 %)
EPS:	$-9.80

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.514

Financial Reports:

No articles found.

Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.